In the Boardroom
Refine Search
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Pharmaceutical
British artificial intelligence specialist BenevolentAI has announced the return of its founder, Ken Mulvany, as executive chairman. 18 October 2024
Biotechnology
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
Pharmaceutical
Canada-based biotech Sernova (TSX: SVA) has announced key new appointments to its executive leadership team. 15 October 2024
Biotechnology
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Biotechnology
Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024
Pharmaceutical
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Biotechnology
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Biotechnology
French cancer vaccine focused biotech Oncovita has appointed Dr Stéphane Altaba as its new chief executive (CEO). 9 October 2024
Biotechnology
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Biotechnology
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Pharmaceutical
US pharma giant Pfizer (NYSE: PFE) has announced that John McGinley has been appointed UK managing director and country president. 7 October 2024
Pharmaceutical
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Pharmaceutical
Halozyme Therapeutics hit the headlines big-time last week, announcing deals with two of the largest global drugmakers that could earn the company as much as $2 billion over the coming years. Also, Germany’s Bayer gained approval in the USA for its non-Hodgkin lymphoma drug Aliqopa, Israel’s Teva Pharmaceutical Industries scored a hit, hiring Lundbeck chief executive to head the rudderless company, along with the sale of its Paragard, UK-based AstraZeneca presented very encouraging data from the PACIFIC study on its durvalumab, while America’s Amicus Therapeutics announced the failure of its rare skin diseases drug candidate SD-101. 17 September 2017
Biotechnology
Alexandre Sudarskis, chief executive of privately-held Swiss biopharma firm Neovii Pharmaceuticals will step down from this post having reached retirement age. 15 September 2017
Biotechnology
USA-based holding company PDL BioPharma has appointed Dominique Monnet to the position of president. 12 September 2017
Biotechnology
US biotech major Biogen has engaged Dr Sanjay Jariwala as senior vice president, worldwide medical. 12 September 2017
Generics
Danish CNS specialist Lundbeck saw its shares drop 11.58% to 364.20 Danish kroner this morning, when it was revealed that its chief executive Kåre Schultz is set to join Israeli generics behemoth Teva Pharmaceutical Industries as the latter’s president and CEO. 11 September 2017
Biotechnology
US ophthalmology specialist Ocular Therapeutix (Nasdaq: OCUL) today announced the appointment of Michael Goldstein as chief medical officer. 8 September 2017
Pharmaceutical
All eyes were on the share price of Swiss pharma giant Novartis on Monday after the announcement that Joe Jimenez was to step down from his role as chief executive. 4 September 2017
Generics
Bain Capital and Cinven announce their intention to nominate Claudio Albrecht as new chief executive and Mark Keatley as new chief financial officer of Stada Arzneimittel, the German generic drugmaker they are in the process of acquiring. 4 September 2017
Pharmaceutical
German family-owned pharma company Grünenthal Group today announces that Mark Fladrich has taken office as new chief commercial officer (CCO). 1 September 2017
Pharmaceutical
Following the succession plan initiated more than a year ago, when Eduardo Sanchiz expressed his wish to devote more time to his family and other interests, the board of directors of Spain’s largest pharma firm Almirall has approved the appointment of Peter Guenter as chief executive effective Octoberjavascript:void(0); 1, 2017. 29 August 2017
Pharmaceutical
Switzerland’s Novartis has appointed Bertrand Bodson as chief digital officer, reporting directly to the CEO. 24 August 2017
Pharmaceutical
Almirall has appointed Ron Menezes as the new president and general manager of its USA-based subsidiary Aqua Pharmaceuticals. 22 August 2017
Biotechnology
UK-based artificial intelligence firm BenevolentAI has hired Ian Churcher as VP of drug discovery & preclinical development for its bioscience subsidiary, BenevolentBio. 22 August 2017
Biotechnology
Ireland-headquartered Shire has announced changes to its executive committee, as it progresses its strategy to sharpen its focus as a leader in rare diseases. 21 August 2017
Pharmaceutical
UK-registered Akari Therapeutics has appointed Dr David Horn Solomon as the company’s new chief executive, effective August 28, 2017. 21 August 2017
Pharmaceutical
Danish diabetes giant Novo Nordisk has announced two changes to its executive team. 15 August 2017
Pharmaceutical
Merz Neuroscience, a division of Merz North America, today announced that Kevin O’Brien will join the company as the vice president and US head of neurosciences, effective immediately. 15 August 2017
Biotechnology
UK and USA-based clinical-stage biotech Orchard Therapeutics today announces the appointment of Mark Rothera as president and chief executive. 10 August 2017
Pharmaceutical
It seemed inevitable that change was on the horizon when Emma Walmsley’s appointment as chief executive of UK pharma major GlaxoSmithKline, taking over from Sir Andrew Witty, was announced nearly a year ago. 7 August 2017
Biotechnology
Dutch human gene therapy specialist uniQure has made several new executive appointments. 7 August 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze